We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects of Botox in Obstructed Defecation Syndrome

This study is currently recruiting participants.
Verified October 2017 by Liliana Bordeianou, Massachusetts General Hospital
Sponsor:
ClinicalTrials.gov Identifier:
NCT02160288
First Posted: June 10, 2014
Last Update Posted: October 18, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Liliana Bordeianou, Massachusetts General Hospital
  Purpose
The purpose of this study is to determine if Botulinum Toxin-A (Botox) injection will improve symptoms of constipation in obstructed defecation syndrome (ODS).

Condition Intervention Phase
Obstructed Defecation Syndrome (ODS) Drug: Botulinum Toxin-A Drug: Normal Saline Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Effects of Type A Botulinum Toxin in Obstructed Defecation Syndrome: a Phase II Randomized, Parallel-Group, Triple-Blind, Placebo-Controlled Trial

Resource links provided by NLM:


Further study details as provided by Liliana Bordeianou, Massachusetts General Hospital:

Primary Outcome Measures:
  • Changes in the Altomare ODS score (ODS-S) and Patient Assessment of Constipation- Quality of Life score (PAC-QoL) [ Time Frame: Baseline, 1 month after injection ]
    The primary outcome measure will be the percent change from baseline in the sum of ODS-S and PAC-QoL at 1 month after the Botox injection. This measures the symptomatic improvement in ODS.


Secondary Outcome Measures:
  • Changes in the Altomare ODS score (ODS-S) [ Time Frame: Baseline, 1, 3, 6 and 12 months after injection ]
    This is a measure of efficacy.

  • Changes in the Patient Assessment of Constipation- Quality of Life score (PAC-QoL) [ Time Frame: Baseline, 1, 3, 6 and 12 months after injection ]
    This is a measure of efficacy.

  • Changes in Health-Related Quality of Life [ Time Frame: Baseline, 1, 3, 6 and 12 months after injection ]
    SF-36 version 1 will be used to measure changes in the health-related quality of life.This is a measure of efficacy.

  • Changes in Cleveland Clinic Fecal Incontinence Score (CCFI) [ Time Frame: Baseline, 1, 3, 6 and 12 months after injection ]
    This is a measure of Botox-specific adverse events.

  • Changes in Fecal Incontinence Quality of Life Scale (FIQoL) [ Time Frame: Baseline, 1, 3, 6 and 12 months after injection ]
    This is a measure of Botox-specific adverse events.

  • Relaxation of puborectalis with push measured by EMG [ Time Frame: Baseline, 1 month follow-up visit ]
    This is a measure of efficacy.

  • Success of balloon expulsion test [ Time Frame: Baseline, 1 month follow-up visit ]
    This is a measure of efficacy.

  • Change in anal sphincter function [ Time Frame: Baseline, 1 month follow-up visit ]
    The changes in anal sphincter function will be assessed by anorectal manometry. This test will measure the resting sphincter pressure, maximal resting anal pressure, maximum squeeze pressure. The change in anal sphincter function is a measure of treatment efficacy.

  • Change in defecation index [ Time Frame: Baseline, 1 month follow-up visit ]
    The defecation index=maximum rectal pressure during attempted defecation/minimum anal residual pressure during attempted defecation. This is calculated based on measurements obtained from anorectal manometry and is a measure of treatment efficacy.


Estimated Enrollment: 46
Actual Study Start Date: February 2016
Estimated Study Completion Date: August 2019
Estimated Primary Completion Date: August 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Botulinum Toxin-A
Patients will receive Botulinum Toxin-A (Botox) injected in the puborectalis muscle and external anal sphincter. We will use 100 units of Botox, a dose with a good safety profile that has been proven to work in previous studies performed in adults.
Drug: Botulinum Toxin-A
100 Units diluted in a 5 cc syringe at a concentration of 20U/mL
Other Name: Botox
Placebo Comparator: Normal saline
Patients will receive normal saline (placebo) injected in the puborectalis muscle and external anal sphincter.
Drug: Normal Saline
Dispensed in a 5 cc syringe
Other Name: 0.9% Sodium Chloride

Detailed Description:

Constipation represents one of the five most common physician diagnoses for gut disorders. Obstructed defecation syndrome (ODS) is an under-treated condition which accounts for 30%- 50% of all patients with constipation and it is more common as people age. ODS is due to the abnormal contraction of the puborectalis muscle (a muscle around the anus that should relax during defecation).

Biofeedback therapy and medical management are the standards of care for ODS. Typically patients are first managed with dietary modifications (fiber supplementation, increased fluids) and medication (laxatives, enemas). If constipation is not improved, they will undergo biofeedback, which lasts from 3-8 sessions on average. Biofeedback acts on the cause of ODS and it has good short-term success, but around 50%-70% of treated patients re-experience constipation after one year. The main drawbacks of biofeedback for ODS are the facts that it is expensive, time-consuming, available in few select-centers and its success depends very much on the provider. Biofeedback is delivered in multiple 1-hour clinic sessions, so many patients don't finish all recommended sessions and their constipation may recur faster.

Botox also acts on the cause of ODS and was shown to improve constipation within 1-3 weeks after the injection. Botox is delivered as a one-time injection in the puborectalis muscle and external anal sphincter (the muscle right around the anus). The injection can be performed in the clinic under local anesthesia, and the patient goes home afterwards. Currently, Botox is used for treatment of patients who fail biofeedback and medical management, to avoid the options of last resort (resection of the colon with stoma). To this day, no adequately designed study has confirmed that Botox is indeed superior to placebo (normal saline) for the treatment of ODS. The results from this study will provide valuable data on the ability of Botox to improve symptoms of constipation and the duration of its effect. This project has the potential to increase the availability of effective treatments for ODS.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Males and females 18 years or older of all races and backgrounds
  • Competent to give informed consent
  • Meet the Rome III diagnostic criteria for functional constipation
  • Inability to relax the puborectalis muscle at electromyography
  • Altomare Obstructed Defecation Syndrome score of 15 points or above
  • Failure of treatment with 2 conservative measures which may be as follows:

    • 1 laxative (osmotic or stimulant) for 2 weeks
    • 1 fiber supplement for one month
    • And/or trial of biofeedback for at least 4 sessions

Exclusion Criteria:

  • Previous treatment with Botox (possible antibodies)
  • Known hypersensitivity to any of the components of the toxin
  • Medication regimen includes narcotics
  • Previous radiation therapy to the anal canal and rectum
  • Prior proctectomy
  • Presence of unhealed and symptomatic anal fissure
  • Presence of anal pain
  • Presence of fecal incontinence
  • Presence of full thickness rectal prolapse
  • Presence of internal sphincter myopathy
  • Inflammatory bowel disease or proctitis
  • Pregnancy or breast-feeding
  • Subject is currently enrolled/ just finished participating in a clinical trial in which the intervention/ its carry-over effect may interact with the intervention in this trial
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02160288


Contacts
Contact: Liliana Bordeianou, M.D. 617-643-0541 lbordeianou@partners.org
Contact: Lieba Savitt, N.P. 617-643-5580 MGHpelvicfloorcenter@partners.org

Locations
United States, Massachusetts
Massachusetts General Hospital Recruiting
Boston, Massachusetts, United States, 02114
Contact: Liliana Bordeianou, M.D.    617-643-0541    lbordeianou@partners.org   
Contact: Lieba Savitt, N.P.    617-643-5580    MGHpelvicfloorcenter@partners.org   
Principal Investigator: Liliana Bordeianou, M.D.         
Sponsors and Collaborators
Massachusetts General Hospital
Investigators
Principal Investigator: Liliana Bordeianou, M.D. Massachusetts General Hospital
  More Information

Publications:
Responsible Party: Liliana Bordeianou, Assistant Professor of Surgery, Division of General and Gastrointestinal Surgery, Massachusetts General Hospital
ClinicalTrials.gov Identifier: NCT02160288     History of Changes
Other Study ID Numbers: MGH2014-P-000406
First Submitted: June 3, 2014
First Posted: June 10, 2014
Last Update Posted: October 18, 2017
Last Verified: October 2017

Keywords provided by Liliana Bordeianou, Massachusetts General Hospital:
Botox
Obstructed Defecation Syndrome
ODS
Outlet-Type Constipation
injection

Additional relevant MeSH terms:
Syndrome
Disease
Pathologic Processes
Botulinum Toxins
onabotulinumtoxinA
Botulinum Toxins, Type A
abobotulinumtoxinA
Acetylcholine Release Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Neuromuscular Agents
Peripheral Nervous System Agents